GlassScriptPhysician profile
Sari J Stender
NPI 1841273406
$4,231.41
in general payments reported to CMS, 2019-2025
34 companies · $815 in 2025
The $815 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,508 · 2022: $667 · 2023: $535 · 2024: $706 · 2025: $815.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,057.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,056.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $784.67 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $407.25 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $384.05 | 2021-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $318.19 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $314.31 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.59 | 2021-2022 | |
| Exact Sciences Corporation | $171.12 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $156.97 | 2021-2024 | Shingrix, Arexvy |
| Pfizer INC. | $138.23 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $133.01 | 2021 | |
| Amgen INC. | $116.98 | 2021-2025 | Repatha, Otezla |
| Bayer Healthcare Pharmaceuticals INC. | $112.56 | 2022-2023 | |
| Astellas Pharma US INC | $111.96 | 2024-2025 | Veozah |
| Abbott Laboratories | $101.82 | 2022-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $92.68 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $90.29 | 2021 | |
| Phathom Pharmaceuticals, INC. | $81.68 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $78.51 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $67.80 | 2021-2025 | Unithroid |
| Mayne Pharma Commercial LLC | $52.94 | 2025 | |
| Myriad Women'S Health, INC. | $48.09 | 2023 | Myrisk |
| Gynesonics, INC. | $45.18 | 2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Radius Health, INC. | $35.10 | 2021-2023 | Tymlos |
| Dynavax Technologies Corporation | $26.30 | 2025 | Heplisav-B |
| Janssen Pharmaceuticals, INC | $25.53 | 2024 | Spravato |
| Corium, LLC | $24.98 | 2023 | Azstarys |
| Coopersurgical, INC. | $22.02 | 2023 | Paragard T 380a |
| Biohaven Pharmaceuticals, INC. | $21.15 | 2021 | |
| Phadia US INC. | $18.06 | 2025 | Immunocap |
| Idorsia Pharmaceuticals US INC | $17.55 | 2024 | Quviviq |
| Merck Sharp & Dohme LLC | $17.00 | 2021 | |
| Vistapharm, INC. | $16.30 | 2021 | |
| Shield Therapeutics INC | $16.22 | 2025 | |
| Genentech USA, INC. | $6.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sari J Stender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.